In today’s recent session, 0.93 million shares of the Palisade Bio Inc. (NASDAQ:PALI) have been traded, and its beta is 1.52. Most recently the company’s share price was $1.53, and it changed around -$0.04 or -2.55% from the last close, which brings the market valuation of the company to $11.07M. PALI at last check was trading at a discount to its 52-week high of $32.00, offering almost -1991.5% off that amount. The share price’s 52-week low was $1.41, which indicates that the recent value has risen by an impressive 7.84% since then. We note from Palisade Bio Inc.’s average daily trading volume that its 10-day average is 0.24 million shares, with the 3-month average coming to 1.52 million.

Palisade Bio Inc. stock received a consensus recommendation rating of a Buy, based on a mean score of 1.50. If we narrow it down even further, the data shows that 0 out of 2 analysts rate the stock as a Sell; another 0 rate it as Overweight. Among the rest, 0 recommended PALI as a Hold, whereas 2 deemed it a Buy, and 0 rated it as Underweight. Palisade Bio Inc. is expected to report earnings per share of -$0.61 for the current quarter.

Palisade Bio Inc. (NASDAQ:PALI) trade information

Instantly PALI has been showing red trend so far today with a performance of -2.55% on intraday trading today. The performance over the last five days has remained in the red territory. The rise to weekly highs of 1.7900 on Tuesday, 05/23/23 increased the stock’s daily price by 14.53%. The company’s shares are currently down -70.58% year-to-date, but still down -4.97% over the last five days. On the other hand, Palisade Bio Inc. (NASDAQ:PALI) is -0.65% down in the 30-day period. We can see from the shorts that 0.33 million shares have been sold at a short interest cover period of 0.09 day(s).

The consensus price target as assigned by Wall Street analysts is $10.50, which translates to bulls needing to increase their stock price by 85.43% from its current value. Analyst projections state that PALI is forecast to be at a low of $5.00 and a high of $16.00. In order for the stock price to hit the forecast high, the stock would need to plunge -945.75% from its current level, while the stock would need to crash -226.8% from its current level to reach the projected low.

Palisade Bio Inc. (PALI) estimates and forecasts

Palisade Bio Inc. share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -30.77 percent over the past six months and at a 90.50% annual growth rate that is well above the industry average of 11.40%. Moreover, analysts have decided to roll up on their fiscal year 2023 revenue estimates. The rating firms predict that it will gain 89.80% in revenue this quarter, and will report an increase of 86.00% in the next quarter.

PALI Dividends

Palisade Bio Inc.’s next quarterly earnings report is expected to be released around August 14 and August 18.

Palisade Bio Inc. (NASDAQ:PALI)’s Major holders

Upon looking at major shareholders, it appears that insiders hold 1.99% of Palisade Bio Inc. shares, and 3.52% of them are in the hands of institutional investors. The stock currently has a share float of 3.59%. Palisade Bio Inc. stock is held by 17 institutions, with Morgan Stanley being the largest institutional investor. By Mar 30, 2023, it held 0.05% of the shares, which is about 3227.0 shares worth $11359.0.

Tower Research Capital LLC (TRC), with 0.04% or 2479.0 shares worth $8726.0 as of Mar 30, 2023, holds the second largest percentage of outstanding shares.

Fidelity Series Total Market Index Fund and Vanguard Extended Market Index Fund were the top two Mutual Funds as of Feb 27, 2023. The former held 2026.0 shares worth $4376.0, making up 0.04% of all outstanding shares. On the other hand, Vanguard Extended Market Index Fund held roughly 1551.0 shares worth around $8065.0, which represents about 0.03% of the total shares outstanding.